Ice 3682

Drug Profile

Ice 3682

Alternative Names: Ice-3682; JNJ 42503682

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Pharmaceuticals
  • Developer Ice Therapeutics
  • Class Analgesics; Small molecules
  • Mechanism of Action TRPM8 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 04 Jul 2017 Ice Therapeutics in-licenses Ice 3682 from Janssen Pharmaceuticals before July 2017 (FutuRx website, July 2017)
  • 04 Jul 2017 Preclinical trials in Neuropathic pain in Israel (PO) before July 2017 (FutuRx website, July 2017)
  • 04 Jul 2017 Ice Therapeutics announces intention to submit IND/CTA for Neuropathic pain (FutuRx website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top